Pelabresib (CPI-0610) Combined with Ruxolitinib for JAK Inhibitor Treatment-Naive Patients with Myelofibrosis: Durability of Response and Safety Beyond Week 24

被引：0

作者：

Mascarenhas, John ^{[1
]}

Kremyanskaya, Marina ^{[2
]}

Patriarca, Andrea ^{[3
,4
]}

Gupta, Vikas ^{[5
]}

Palandri, Francesca ^{[6
]}

Devos, Timothy ^{[7
,8
]}

Rampal, Raajit K. ^{[9
]}

Talpaz, Moshe ^{[10
]}

Vannucchi, Alessandro ^{[11
]}

Kuykendall, Andrew ^{[12
]}

Kiladjian, Jean-Jacques ^{[13
]}

Verstovsek, Srdan ^{[14
]}

Mesa, Ruben ^{[15
]}

Colak, Gozde ^{[16
]}

Li, Qing ^{[17
]}

Klein, Sandra ^{[16
]}

Harrison, Claire ^{[18
]}

机构：

[1] Icahn Sch Med Mt Sinai, Dept Hematol & Med Oncol, New York, NY 10029 USA

[2] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Div Hematol & Med Oncol, New York, NY 10029 USA

[3] Univ Piemonte Orientale, Dept Translat Med, Hematol Unit, Novara, Italy

[4] AOU Maggiore Carite, Novara, Italy

[5] Univ Toronto, Dept Med, Toronto, ON, Canada

[6] IRCCS Azienda Osped Univ Bologna, Ist Ematol Seregnoli, Bologna, Italy

[7] Katholieke Univ Leuven, Univ Hosp Leuven, Leuven, Belgium

[8] Katholieke Univ Leuven, Rega Inst, Lab Mol Immunol, Leuven, Belgium

[9] Mem Sloan Kettering Canc Ctr, Ctr Hematol Malignancies, 1275 York Ave, New York, NY 10021 USA

[10] Univ Michigan, Comprehens Canc Ctr, Ann Arbor, MI 48109 USA

[11] Univ Florence, Azienda Osped Univ Careggi, Florence, Italy

[12] H Lee Mofitt Canc Ctr, Dept Malignant Hematol, Tampa, FL USA

[13] Univ Paris, Hop St Louis, Paris, France

[14] MD Anderson Canc Ctr, Houston, TX USA

[15] UT Hlth San Antonio MD Anderson Canc Ctr, Mays Canc Ctr, San Antonio, TX USA

[16] Constellat Pharmaceut Inc, Boston, MA USA

[17] MorphoSys US Inc, Boston, MA USA

[18] Guys & St Thomas NHS Fdn Trust, London, England

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-158147

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[31] A phase 3, randomized, double-blind, placebo-controlled study of ruxolitinib plus parsaclisib in patients with JAK- and PI3K-inhibitor treatment-naive myelofibrosis
Yacoub, Abdulraheem
Erickson-Viitanen, Susan
Zhou, Feng
Assad, Albert
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[32] Navitoclax plus ruxolitinib in JAK inhibitor-naive patients with myelofibrosis: Preliminary safety and efficacy in a multicenter, open-label phase 2 study.
Passamonti, Francesco
Foran, James M.
Tandra, Anand
De Stefano, Valerio
Fox, Maria Laura
Mattour, Ahmad Hatem
McMullin, Mary Frances
Perkins, Andrew
Rodriguez-Macias, Gabriela
Sibai, Hassan
Qin, Qin Q.
Potluri, Jalaja
How, Jonathan B.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[33] A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ruxolitinib Plus Parsaclisib in Patients with JAK- and PI3K-Inhibitor Treatment-Naive Myelofibrosis.
Yacoub, Abdulraheem
Erickson-Viitanen, Sue
Zhou, Feng
Assad, Albert
CANCER RESEARCH, 2021, 81 (13)
[34] BEYOND A BINARY ENDPOINT: LONGITUDINAL AND INDIVIDUAL SYMPTOM ANALYSES FROM THE SIMPLIFY-1 STUDY DEMONSTRATE CLINICALLY COMPARABLE SYMPTOMATIC BENEFIT OF MOMELOTINIB TO RUXOLITINIB IN JAK INHIBITOR NAIVE MYELOFIBROSIS PATIENTS
Mesa, R.
Hudgens, S.
Floden, L.
Palmer, J.
Gupta, V
McLornan, D. P.
McMullin, M. F.
Kiladjian, J. J.
Foltz, L.
Platzbecker, U.
Fox, M. L.
Mead, A. J.
Ross, D. M.
Oh, S. T.
Perkins, A.
Leahy, M. F.
Deheshi, S.
Donahue, R.
Klencke, B. J.
Verstovsek, S.
VALUE IN HEALTH, 2021, 24 : S22 - S22
[35] Raltegravir Versus Efavirenz Regimens in Treatment-Naive HIV-1-Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic Analyses
Lennox, Jeffrey L.
DeJesus, Edwin
Berger, Daniel S.
Lazzarin, Adriano
Pollard, Richard B.
Ramalho Madruga, Jose Valdez
Zhao, Jing
Wan, Hong
Gilbert, Christopher L.
Teppler, Hedy
Rodgers, Anthony J.
Barnard, Richard J. O.
Miller, Michael D.
DiNubile, Mark J.
Nguyen, Bach-Yen
Leavitt, Randi
Sklar, Peter
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2010, 55 (01) : 39 - 48
[36] POIESIS: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Phase 3 Study of Navtemadlin As Add-on to Ruxolitinib in JAK Inhibitor-Naive Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
Vachhani, Pankit
Rampal, Raajit
Bradley, Terrence
Harrison, Claire
Jain, Tania
Kuykendall, Andrew T.
Palandri, Francesca
Mascarenhas, John O.
Al-Ali, Haifa Kathrin
Passamonti, Francesco
Nekhymchuk, Anna
Foss, Hilarie
Rothbaum, Wayne
Verstovsek, Srdan
Heidel, Florian
BLOOD, 2024, 144 : 18083 - 18084
[37] Predictors of Response to 24-Week Telaprevir-Based Triple Therapy for Treatment-Naive Genotype 1b Chronic Hepatitis C Patients
Abe, Hiroshi
Tsubota, Akihito
Shimada, Noritomo
Atsukawa, Masanori
Kato, Keizo
Takaguchi, Koichi
Asano, Toru
Chuganji, Yoshimichi
Sakamoto, Choitsu
Toyoda, Hidenori
Kumada, Takashi
Ide, Tatsuya
Sata, Michio
Aizawa, Yoshio
GASTROENTEROLOGY RESEARCH AND PRACTICE, 2014, 2014
[38] Raltegravir Versus Efavirenz Regimens in Treatment-Naive HIV-1-Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic Analyses (vol 55, pg 39, 2010)
Lennox
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2011, 58 (04) : E120 - E120
[39] Safety and antiviral effect of Elpida (VM-1500), a novel NNRTI ( plus Truvada) in treatment-naive HIV-1-infected patients at 24-to 48-week therapy
Kravchenko, Alexey
Orlova-Morozova, Elena
Nagimova, Fiyara
Kozirev, Oleg
Shimonova, Tatyana
Bichko, Vadim
Vostokova, Natalya
Zozulya, Olga
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2016, 19
[40] A 14-day dose-response study of the efficacy, safety, and pharmacokinetics of the nonpeptidic protease inhibitor tipranavir in treatment-naive HIV-1-infected patients
McCallister, S
Valdez, H
Curry, K
MacGregor, T
Borin, M
Freimuth, W
Wang, YY
Mayers, DL
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2004, 35 (04) : 376 - 382

← 1 2 3 4 5 →